VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
1-Year Return
12.28%
This Quarter Return
-7.05%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.34B
AUM Growth
+$132M
(+11%)
Cap. Flow
+$239M
Cap. Flow
% of AUM
17.84%
Top 10 Holdings %
Top 10 Hldgs %
54.87%
Holding
79
New
21
Increased
28
Reduced
5
Closed
19
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$69.5M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$42.7M |
| 3 |
Exact Sciences
EXAS
|
$34.9M |
| 4 |
Arcellx
ACLX
|
$31.7M |
| 5 |
Ascendis Pharma
ASND
|
$30.7M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$97.9M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$52.3M |
| 3 |
AstraZeneca
AZN
|
$27.1M |
| 4 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$21.7M |
| 5 |
argenx
ARGX
|
$19.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Day One Biopharmaceuticals
DAWN
$744M
| $17.2M | 1.28% |
+1,250,000
| New | +$17.2M |
|
|
NARI
27
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $16.9M | 1.26% |
350,000
-450,000
| -56% | -$21.7M |
|
28
Dianthus Therapeutics
DNTH
$773M
| $15.5M | 1.16% |
600,000
+145,000
| +32% | +$3.75M |
|
29
Solid Biosciences
SLDB
$426M
| $15.1M | 1.13% |
2,665,000
+1,630,000
| +157% | +$9.24M |
|
30
Lexeo Therapeutics
LXEO
$268M
| $13.5M | 1% |
840,000
+665,000
| +380% | +$10.7M |
|
31
Apellis Pharmaceuticals
APLS
$3.47B
| $12.9M | 0.96% |
335,000
+110,000
| +49% | +$4.22M |
|
32
Immunome
IMNM
$853M
| $12.1M | 0.9% |
+1,000,000
| New | +$12.1M |
|
33
Denali Therapeutics
DNLI
$2.17B
| $11.6M | 0.87% |
+500,000
| New | +$11.6M |
|
34
Nurix Therapeutics
NRIX
$694M
| $10.4M | 0.78% |
+500,000
| New | +$10.4M |
|
35
Black Diamond Therapeutics
BDTX
$161M
| $9.79M | 0.73% |
+2,100,000
| New | +$9.79M |
|
36
BioNTech
BNTX
$24.4B
| $8.04M | 0.6% |
+100,000
| New | +$8.04M |
|
37
Inspire Medical Systems
INSP
$2.6B
| $8.03M | 0.6% |
+60,000
| New | +$8.03M |
|
38
Pacira BioSciences
PCRX
$1.2B
| $8.01M | 0.6% |
280,000
+200,000
| +250% | +$5.72M |
|
39
Dyne Therapeutics
DYN
$1.86B
| $7.94M | 0.59% |
+225,000
| New | +$7.94M |
|
40
Fulcrum Therapeutics
FULC
$360M
| $7.19M | 0.54% |
1,160,000
+465,000
| +67% | +$2.88M |
|
41
Alto Neuroscience
ANRO
$94M
| $6.63M | 0.49% |
620,000
+370,000
| +148% | +$3.96M |
|
42
Fate Therapeutics
FATE
$111M
| $6.56M | 0.49% |
2,000,000
+1,200,000
| +150% | +$3.94M |
|
43
Allogene Therapeutics
ALLO
$240M
| $5.13M | 0.38% |
2,200,000
+850,000
| +63% | +$1.98M |
|
44
Passage Bio
PASG
$22.4M
| $4.81M | 0.36% |
302,600
+77,600
| +34% | +$1.23M |
|
45
Voyager Therapeutics
VYGR
$210M
| $4.75M | 0.35% |
600,000
| – | – |
|
46
Galapagos
GLPG
$2.05B
| $4.46M | 0.33% |
180,000
+50,000
| +38% | +$1.24M |
|
47
Zymeworks
ZYME
$1.08B
| $3.74M | 0.28% |
+440,000
| New | +$3.74M |
|
48
Relmada Therapeutics
RLMD
$41.2M
| $3.6M | 0.27% |
1,200,000
| – | – |
|
49
MacroGenics
MGNX
$118M
| $3.4M | 0.25% |
800,000
+75,000
| +10% | +$319K |
|
50
Monte Rosa Therapeutics
GLUE
$299M
| $3.33M | 0.25% |
+890,000
| New | +$3.33M |
|